Clinical trials: Anakinra
Schnitzler Syndrome
Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
The Schnitzler syndrome is a rare entity characterized by an urticarial rash and recurrent fever in a patient with a monoclonal IgM component.
- Trial name
- NCT00933296
- Where
- 17 sites in France, Italy
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Rheumatoid Arthritis
Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire
The primary purpose of this study is to assess the ease-of-use of SimpleJectTM compared to pre-filled syringe(s) when using Kineret® in RA subjects.
- Trial name
- NCT00121043
- Testing
- SimpleJectTM, Kineret® (Anakinra)
- Sponsor
- Amgen
Refractory Hemochromatosis Rheumatism
Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study
Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.
- Trial name
- THERA (NCT02263638)
- Testing
- Anakinra
- Where
- 3 sites in France
- Volunteers
- 17 people
- Sponsor
- Rennes University Hospital
Still Disease, Juvenile Onset
Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
The purpose of the study is to evaluate and characterize long-term safety of Kineret when used in standard clinical practice to treat patients with systemic juvenile idiopathic arthritis (SJIA).
- Trial name
- NCT03932344
- Testing
- Anakinra
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Swedish Orphan Biovitrum
Chronic Granulomatous Disease
IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease
"Kineret" (INN: Anakinra) neutralizes the biological activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by the concurrent inhibition of binding to interleukin-1 receptor I (IL-1RI).
- Trial name
- NCT04136028
- Testing
- Kineret
- Where
- Russia
- Volunteers
- 13 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Rheumatoid Arthritis
Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to estimate the effect of anakinra, 100 mg once daily (QD), on the development of an anti-tetanus antibody response in subjects with RA after vaccination with a tetanus and diphtheria toxoids…
- Trial name
- NCT00111410
- Testing
- Anakinra (r-metHuIL-1ra)
- Sponsor
- Amgen
Rheumatoid Arthritis
Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
The purpose of this study is to evaluate the effect of anakinra (IL-1 ra) and pegsunercept (PEG sTNF-RI) when they are used together in improving the signs and symptoms of rheumatoid arthritis.
- Trial name
- NCT00037700
- Testing
- anakinra, pegsunercept
- Sponsor
- Amgen
Pulmonary Hypertension
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension
This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with pulmonary hypertension.
- Trial name
- NCT01479010
- Testing
- Anakinra 100 mg subcutaneously daily
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
Asthma (Diagnosis), Persistent Asthma
Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)
In this single center, interventional pilot study, 40 participants at high risk for future exacerbation will be randomized to anakinra (v.
- Conditions
- Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
- Trial name
- ARTMA (NCT07600190)
- Testing
- Anakinra 100 Mg/0.67 Ml Inj Syringe
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes
Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
Aim: To investigate the therapeutic potential of IL-1Ra in type 2 diabetes. Rationale: Since the major defect leading to a decrease in b-cell mass in type 2 diabetes is increased apoptosis, therapeutic approaches designed to…
- Trial name
- NCT00303394
- Testing
- IL-1Ra
- Where
- 2 sites in Denmark, Switzerland
- Volunteers
- 72 people
- Sponsor
- University of Zurich
HIV Infections, Neurologic Disorders
Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection
Background: HIV can sometimes cause HIV-associated neurocognitive disorder, or HAND. HAND is HIV-associated neurocognitive disorder. It can affect memory, thinking, or concentration. It can cause mood changes.
- Trial name
- NCT02527460
- Testing
- Anakinra
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Background: Multiple sclerosis (MS) is a disease of the central nervous system (CNS). People who have MS may have lesions that form on parts of the CNS, such as the brain. Some of these lesions may be inflamed for a long time.
- Trial name
- NCT04025554
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Premature Infants, Very Premature Infants
Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants
A phase 2 randomised, three-arm, parallel-group, dose-ranging trial to determine safety, efficacy and optimal dosing of intravenous anakinra in premature neonates, with subcutaneous pharmacokinetic sub-study.
- Conditions
- Premature Infants, Very Premature Infants, Inflammation
- Trial name
- AP2 (NCT07254000)
- Testing
- Anakinra (Kineret®)
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 24 people
- Sponsor
- Monash Medical Centre
Covid19, Pneumonia
Anakinra in the Management of COVID-19 Infection
Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health.
- Conditions
- Covid19, Pneumonia, Cytokine Release Syndrome, Corona Virus Infection
- Trial name
- NCT04643678
- Testing
- Anakinra, Standard of Care
- Where
- Qatar
- Volunteers
- 80 people
- Sponsor
- Hamad Medical Corporation
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation…
- Trial name
- Cytomegalovir (NCT05419206)
- Testing
- CMV DNA analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 167 people
- Sponsor
- Ramazan Gozukucuk
Unspecified Adult Solid Tumor, Protocol Specific
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
RATIONALE: Biological therapies, such as anakinra, may interfere with the growth of the tumor cells and slow the growth of metastatic tumors that express the interleukin-1 gene.
- Trial name
- NCT00072111
- Testing
- anakinra
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Nasal Stuffiness, Sneezing
Cyanobacteria Allergy in Lake Kineret
People swimming or surfing in lake Kineret , sometimes complain of nasal stuffiness , sneezing and itching .Typically, it happens during or immediately after contact with the lake's water .
- Conditions
- Nasal Stuffiness, Sneezing, Itching
- Trial name
- NCT01693198
- Testing
- Skin test with sterile extracts of different cyanobacteria
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Meir Medical Center
Systemic-Onset Juvenile Idiopathic Arthritis
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
1. Main objective: To test the efficacy of anakinra treatment in children or young adults with corticosteroid-resistant or -dependent Systemic-Onset Juvenile Idiopathic Arthritis (SO-JIA) 2.
- Trial name
- NCT00339157
- Testing
- Anakinra, Pneumo23
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Postprandial Hypoglycemia
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.
- Trial name
- Hypo-PrEA (NCT05174507)
- Testing
- empagliflozin, anakinra
- Sponsor
- University Hospital, Basel, Switzerland
Asthma, Allergic
Anakinra as a Rescue Treatment for Allergic Inflammation
Participants with mild asthma who are sensitized to either house dust mite or cat hair allergen will undergo nasal instillation of the allergen to elicit nasal allergy symptoms.
- Trial name
- NCT04035109
- Testing
- Anakinra, House dust mite allergen, Cat hair allergen
- Sponsor
- University of North Carolina, Chapel Hill